2nd ESMO Consensus Conference on Lung Cancer: pathology and molecular biomarkers for non-small-cell lung cancer

K.M. Kerr1,*, L. Bubendorf2, M.J. Edelman3, A. Marchetti4, T. Mok5, S. Novello6, K. O’Byrne7, R. Stahel8, S. Peters9, E. Felip10, Panel Members†,*

1Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Aberdeen, United Kingdom
2Institute for Pathology, University Hospital Basel, Basel, Switzerland
3University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
4Center of Predictive Molecular Medicine, Center of Excellence on Ageing, University-Foundation, Chieti, Italy
5Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin New Territories, Hong Kong, China
6Thoracic Oncology Unit, Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Orbassano, Italy
7Trinity College, Dublin, Ireland and Queensland University of Technology, Brisbane, Australia
8Clinic of Oncology, University Hospital Zürich, Zürich, Switzerland
9Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
10Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
*Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganell-Lugano, Switzerland; E-mail: clinicalguidelines@esmo.org
†See Appendix for Panel Members

Key Message: "This 2nd ESMO Consensus Conference on Lung Cancer manuscript focuses on non-small-cell lung cancer pathology and molecular biomarkers."
Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally-advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

Key words: ESMO, Consensus, Non-small-cell lung cancer, Pathology, Molecular testing, Recommendations
Lung cancer is the leading cause of cancer-related death and most currently used chemotherapeutic agents lack adequate specificity and efficacy. The past decade has seen the emergence of histology (squamous cell vs. non-squamous) as an important determinant of therapy in non-small-cell carcinomas (NSCLC). In addition, a significant proportion of patients have tumours with therapeutically targetable molecular characteristics (mutations, fusion genes, etc.) [1], and currently, the vast majority of these actionable molecular abnormalities occur in pulmonary adenocarcinomas. Laboratory testing to identify those likely to respond to such targeted therapy, based upon a predictive biomarker, represents a paradigm shift in lung cancer diagnosis and has now become a standard of care [2-6]. Potential targets more often found in squamous cell carcinomas are emerging. Pathological diagnosis of lung cancer is now a multi-step process, beginning with morphological diagnosis to determine histological type, refined by immunohistochemistry (IHC) where required (see Recommendation 2), followed by appropriate molecular characterisation of the tumour. This increasingly complex diagnostic algorithm poses many challenges for those managing patients with lung cancer [1-7]. Important amongst these is the availability of sufficient tumour tissue to perform all required tests. The majority of NSCLC are diagnosed at an advanced stage, so that large tumour samples (e.g. from surgical resection) are available in only a minority of cases. In patients with advanced disease, interventions required to obtain tumour tissue are often difficult due to tumour location and patient comorbidity, thus most diagnostic lung cancer samples are very small with minimal tumour content. It is now imperative that, whenever possible and without compromising patient safety, any diagnostic biopsy/tissue sampling procedure carried out should aim to maximise the amount of tissue acquired [3]. The role of a multidisciplinary team, including thoracic
surgeons, radiologists, pathologists, oncologists and pulmonologists, is essential in determining the best approach in individual patients. Tissue sampling may be achieved from the primary tumour via bronchoscopy, VATS, thoracotomy or via image guided, percutaneous, transthoracic, transbronchial or transoesophageal techniques [3, 7]. Some of these approaches, as well as many other interventions accessing extra-thoracic sites, may be selected, where appropriate, to sample metastatic disease. There is no current evidence to suggest that there is any significant difference in the clinical relevance of biomarker tests performed on the primary lung tumour versus any resultant metastatic disease. The choice of site sampled will usually be determined by ease of access, patient safety and likely tissue yield.

Tissue samples will range from the whole or large parts of the tumour, to smaller tissue biopsy and a variety of cytology type samples. The yield from any procedure will vary according to the nature of the technique (open surgical, closed, image guided, etc.), the equipment used (gauge or type of sampling needle, etc.) and the skill and tenacity of the operator. Tissue biopsy and cytology type specimens are suitable for diagnosis and molecular testing but must be handled appropriately in order to facilitate the necessary molecular diagnostic procedures.

This guideline follows from that published in 2011 [8]. For the following recommendations, levels of evidence and grades of recommendation have been applied using the system shown in Table 1. Statements without grading were considered to be justified standard clinical practice by the experts and the ESMO faculty.
Recommendation 1: Guidance on tissue handling

- Specimen processing
  - Standard fixation using 10% neutral buffered formalin (4% formaldehyde) is recommended [V, A].
  - Fixation time should be no less than 6 hours, and no greater than 48 hours [IV, A].
  - Sections for biomarker testing should ideally be cut immediately prior to analysis [IV, A].
- Cytology samples (cellblocks, stained direct smears or liquid-based preparations) can be used reliably to detect EGFR mutations and ALK rearrangements [III, A]. At this time, a cell block is the most widely applicable cell source.
- The same pathologist should, if possible, review all available tumour material from the same patient including biopsies and cytology specimens to select the most suitable for biomarker analyses [IV, A].
- A pathologist should be involved in sample preparation for DNA extraction [V, A].
- Enrichment of samples by micro- or macrodissection to maximise tumour cell content before DNA extraction is recommended [III, A].

Pre-analytical factors are critical for reliable biomarker testing on any diagnostic specimen, yet standardisation of tissue processing remains a challenge. The time to fixation (cold ischaemia time) should be minimised, ideally only a few minutes and certainly less than an hour, to avoid degradation of proteins and nucleic acids [9, 10]. Fixation inhibits decay or autolysis of cells and preserves tissue morphology. Specimens should be fixed in 10% neutral buffered formalin (4% formaldehyde solution), which is widely available, and which
preserves protein, RNA and DNA for subsequent biomarker analysis. In general, fixation time should be between 6 and 48 hours [3, 11]. Longer or shorter fixation time may adversely affect the quality of IHC, in situ hybridisation (ISH) and mutation testing; under-fixation also results in poor tissue morphology [3, 12]. If rapid processing routines with short fixation times are employed, these hazards should be borne in mind and results interpreted with due caution. Acidic fixatives (e.g. Bouin) are not recommended since they lead to rapid nucleic acid degradation [13], and accelerated fixation with heated formalin is discouraged as it degrades morphology and molecular studies [14]. Samples from bone metastases which have been decalcified by acidic agents known to degrade DNA should be avoided for molecular analysis if at all possible. Ethylenediaminetetraacetic acid (EDTA) is an effective decalcifying agent, has no adverse effect on DNA quality and should be used in samples of suspected lung cancer where decalcification is required and molecular studies are anticipated.

Aging of formalin fixed, paraffin-embedded (FFPE) tissue sections causes degradation of epitopes and DNA. Sections should be freshly cut, and biomarker analysis performed within 4-6 weeks to avoid non-informative or false-negative results. Integrity of stored tissue sections can be prolonged by paraffin coating, or by sealing using special tapes [3, 13]. Up to 40% of all NSCLC diagnoses are made by cytology alone. Biomarker analyses are applicable to cytological specimens including cellblocks, smears, cytospins or liquid-based cytology [15]. Cellblocks are preferred for marker analysis by many institutions since the same protocols as for histology can be used. Ethanol-based fixation of cytological smears also permits mutation analysis, fluorescence in situ hybridisation (FISH) and IHC, although pathologists must be aware that laboratory protocols may well differ from those for
formalin-fixed tissue [3, 15-17]. The same pre-analytical factors (time to fixation, fixation time, and material aging) apply to cytology specimens.

A pathologist, preferably with expertise in lung cancer, should, if at all possible, review all available material on an individual patient, in order to select that which is optimal for analysis. This will include marking sections for macro/microdissection as required (see below). Where cytology and biopsy samples are reported independently, close communication between responsible pathologists is encouraged to facilitate best sample selection. Pathologists are also responsible for the training and supervision of technical staff preparing and processing the specimens prior to molecular analysis.

For DNA or RNA-based biomarker testing, it is usually important to enrich the tumour cell content of the tissue used for nucleic acid (NA) extraction. Sections of tissue with high tumour content may be used directly. In poorer samples, where feasible, suitable areas identified by pathologists may be scraped (manual macrodissection) from tissue slides. Laser capture microdissection can facilitate high purification of tumour for NA extraction, even from very poor samples, but this technology is not widely available, and requires pathologist skills, and the additional labour and cost involved must be weighed against the potential to avoid repeat biopsy sampling.

**Recommendation 2:** What is an acceptable rate for NSCLC not otherwise specified (NOS) diagnosis in the small biopsy/cytology diagnostic setting and how can this be achieved?

- A diagnosis of NSCLC-NOS should be given in <10% of cases [IV, A].
- This figure is achieved with the judicious use of immunohistochemistry in morphologically indeterminate cases. A recommended approach should include
TTF-1 to predict adenocarcinoma. For predicting squamous cell carcinoma, p63 or p40 and CK5/6 testing are useful [IV, A].

A specific histologic diagnosis (i.e. squamous vs. adenocarcinoma) is of importance in therapeutic decision-making. Drugs such as pemetrexed and bevacizumab are only licensed for use in patients with non-squamous NSCLC, on grounds of efficacy and toxicity respectively [18, 19]. The recommended triage of tumours selected for molecular testing is partly histologically-based.

Diagnostic criteria in the WHO classification of lung carcinomas [20] require examination of the entire tumour. However, most lung cancers are not surgically resected and diagnosis, classification and molecular biomarker testing is performed on small diagnostic biopsy or cytology type samples (see above). The lack of applicable diagnostic criteria, and a tendency for pathologists to diagnose on inadequate evidence, probably accounts for the reported inaccuracy of morphological classification of NSCLC subtypes on small samples [21-28]. NSCLC lacking definitive morphological evidence of squamous or glandular differentiation in a small tumour sample should be classified as NSCLC-NOS [21, 28]. These cases should NOT be classified as large-cell carcinoma [29, 30]. Reported NSCLC-NOS rates are highly variable, reflecting variation in pathologist approach and the case mix of published studies but rates of 25%-30% in small biopsy samples and up to 40% in cytology type samples probably reflect a ‘real world’ situation for consecutive, unselected cases.

Predictive IHC can reduce the NSCLC-NOS rate to <10%, typically 5%-6%, but never to zero. Most NSCLC-NOS samples are the result of non-representative sampling of differentiated lung cancers, mostly adenocarcinomas [22]. Markers such as p63, p40, and cytokeratin CK 5/6 are associated with squamous cell carcinomas, whilst TTF1, Napsin A and CK7, as well as
mucin stains, are associated with adenocarcinomas [31-36]. These markers are, however, not specific for either diagnosis. TTF1 is expressed in only 75%-80% of lung adenocarcinomas. These markers only have predictive value when expressed at certain levels in the diagnostic sample; levels which have been determined by predictive power in small samples when compared with final resection diagnosis [31-33].

When a NSCLC subtype is predicted by this approach, the recommended diagnosis is ‘NSCLC, probably (or favour) squamous cell carcinoma’ or ‘probably adenocarcinoma’. The predictive accuracy is ~85%. Thus, in small biopsy or cytology samples, a more limited range of primary carcinoma diagnoses should be given (Table 2) [29, 30]. Cases with a ‘favoured’ diagnosis should be treated as those with definitive subtyping.

**Recommendation 3: Routine EGFR somatic mutation testing has been recommended.**

- All non-squamous tumours in patients with advanced/recurrent disease should be tested for *EGFR* mutation [I, A].

- Selected squamous tumours (from patients with minimal or remote smoking history) should strongly be considered for testing [IV, B].

- A wide coverage of mutations in exons 18-21 is strongly encouraged, including those associated with resistance to some therapies. At a minimum, when resources or material are limited, the most common activating mutations (Exon19del, L858R) should be determined [I, A].
Any methodology employed should be validated by an external quality assurance program [V, A].

Activating mutations in the epidermal growth factor receptor gene (EGFR) tyrosine kinase domain are found in 10%-16% of cases of adenocarcinoma in European patients [37-39]. These mutations are only rarely reported in bona fide squamous cell carcinomas. The cause of EGFR mutation is unknown, but is not related to tobacco carcinogenesis. These mutations are therefore more common in, though by no means exclusive to, never smokers and distant ex-smokers, and females of younger age [40-41]. These clinical parameters should not, therefore, be used to select patients for EGFR mutation testing. However, recent anecdotal evidence indicates that patients with any type of primary lung carcinoma, including small-cell carcinoma, who have a minimal or remote smoking history, should be strongly considered for testing.

Phase III trials involving Asian, European and North American patients with metastatic disease whose tumours have activating EGFR mutations have demonstrated high response rates (~70%) and significantly longer progression-free survival (PFS) (though not overall survival) in patients treated with EGFR tyrosine kinase inhibitors (EGFR TKIs, gefitinib, erlotinib, afatinib) as initial treatment when compared to those receiving chemotherapy [42–46]. The use of EGFR TKIs is now well established in clinical practice, requiring routine testing of appropriate cases for EGFR mutations.
Most clinically significant EGFR mutations are either deletions in exon 19 or the L858R substitution mutation (80%-90% of mutations) [47-48], but rarer mutations in exons 18 and 21 may also predict response to EGFR TKIs. Some mutation testing strategies may be allele specific for a pre-determined range, or detect only certain types of mutation (e.g. fragment length analysis for exon 19 deletions), whilst other techniques can detect any mutation in EGFR exons 18-21. Methodology used will often depend on that available in individual centres. Users should be aware of any limitation in mutation coverage offered by the technology used, as well as the sensitivity for detecting mutations against a background of wild-type genome (see concluding remarks). This caution also applies to the use of EGFR mutation-specific antibodies in immunohistochemistry to detect EGFR mutations. Given the range of clinically important mutations not reliably detected by currently available antibodies, this approach as a primary method of detection is not recommended.

Some mutations, especially those in exon 20, most commonly exon 20 insertions and the T790M substitution, are activating but confer resistance to first generation EGFR TKIs [48]. These mutations are uncommon, but may exist as minor clones in EGFR TKI-naive tumours, detectable only by very high-sensitivity, targeted methods. A T790M mutation is found in ~50% of tumours relapsing during EGFR TKI therapy [49]. Testing strategy around EGFR TKI resistance is still in development, but, it is likely that specific recommendations on T790M mutation testing will evolve, since agents targeting this mutation, as well as the more common sensitising mutations, have reported activity in this setting.
Recommendation 4: Is there sufficient evidence to support routine testing for ALK rearrangement?

- All non-squamous tumours in patients with advanced/recurrent disease should be tested for ALK rearrangement [II, A].
- Selected squamous tumours (from patients with minimal or remote smoking history) should strongly be considered for testing [III, B].
- Definitive assessment of ALK rearrangement is determined by FISH [I, A].
- IHC methods may be employed for screening and may become validated for therapy [IV, B].
- Methodologies employed should be validated by an external quality assurance program [V, A].

ALK gene rearrangement occurs in approximately 3%-5% of adenocarcinomas and predicts response to ALK-targeted inhibitors. ALK-rearranged tumours are associated with distinct clinicopathological features, including onset at a young age, never or light smoking history, and adenocarcinoma, particularly with signet ring or acinar histology [50-55]. As with EGFR mutations, however, these clinicopathological features are insufficiently sensitive to screen for testing an individual patient as a significant proportion of ALK-rearranged tumours may go undetected. ALK gene rearrangements are very infrequent in squamous cell carcinoma [50, 51, 55], have been reported in adenosquamous carcinoma [54], and are largely mutually exclusive with EGFR or KRAS mutations [56].
The ALK tyrosine kinase inhibitor crizotinib is effective in patients whose tumours show an ALK gene rearrangement. In Europe, crizotinib is currently indicated for second-line therapy in NSCLC patients who have received one prior platinum-based regimen. There is no current indication in early disease or as first-line therapy in advanced disease. ALK testing will therefore not necessarily be required at initial tumour diagnosis but could be performed in anticipation of future need.

In the majority of the cases, ALK fuses with EML4 through a small intra-chromosomal inversion event and FISH analysis detecting chromosome 2 inversions and other ALK translocations is the current standard for diagnosis of ALK rearrangement. The US Food and Drug Administration mandates the ALK Break Apart FISH Probe Kit (Abbott Molecular, Des Plaines, IL) companion diagnostic for crizotinib in lung cancer [57], but the European Medicines Agency is less specific, requiring only ‘a validated ALK test’ [58]. FISH testing is relatively expensive, and can be difficult to interpret, as the most common alteration, the intrachromosomal inversion, leads to subtle alterations with a consequent risk of both false-negative and false-positive results [59]. IHC detection of elevated ALK protein in ALK-rearranged tumour cells offers a practical and cost-effective approach to pre-screening cases for confirmation by FISH analysis, based on the high probability of rearrangement when IHC testing is positive, and a very low probability of ALK rearrangement when IHC testing is negative [16, 60-64]. Protein levels are relatively low and detection requires a high-affinity antibody and a sensitive IHC detection system. The potential for IHC as a screening tool, or even as a primary biomarker is still evolving. IHC pre-screening is widely accepted, and practiced in many centres. Recommendations for utilising these methods have been published [65, 66].
Recommendation 5: Do we require guidelines for testing other somatic gene mutations or other targetable genetic alterations (KRAS, BRAF, HER2, ROS1 fusion, RET fusion, etc.)

- Routine testing for these biomarkers is not currently recommended [III-IV, C].
- Patients with demographic variables (e.g. minimal or remote smoking history) whose tumours have tested negative for EGFR mutation and ALK rearrangement might be considered for testing for ROS1 rearrangements, RET rearrangements, BRAF mutation and other abnormalities for which specific therapeutics are currently available, even if evidence of activity is from case series (see text) [III, A].
- Emerging data from clinical trials of agents targeting tumours with other abnormalities may lead to recommendations for additional testing.

The revolution in gene and other biomarker analysis has led to the identification of a number of biomarkers for which potentially active agents are already approved for other indications (e.g. crizotinib for ALK gene rearrangements). These biomarkers include ROS1 and RET gene rearrangements, HER2 amplification and mutation, BRAF mutations and others [4, 67, 68]. In addition, though no active agent has been clinically proven, KRAS mutation analysis has become common given the widespread availability of validated tests. MET and PDL1 expression are other potential future biomarker. As none of the respective targeted agents have regulatory approval, routine testing is not advised.

However, prospective case series have demonstrated patient benefit (in terms of response and prolonged PFS) for treatment with crizotinib, and vemurafenib and dabrafenib, in ROS1-rearranged and BRAF-mutated tumours respectively. The panel members therefore felt that testing those at substantial risk of some abnormalities, if that risk can be identified (e.g..
never, scant or remote smokers lacking *EGFR* or *ALK* abnormalities) is reasonable if a sequential testing strategy is employed [68-70]. The panel members recognise that there is increasing evidence that a history of significant tobacco use does not exclude the possibility of activating and actionable mutations/rearrangements, particularly for *BRAF* mutation. This population can be further enriched by excluding from further testing patients bearing a *KRAS* mutation, should this test be available [71]. While mutations are not entirely mutually exclusive, the incidence of disease characterised by “double mutations” is <1% [72], making this a logical and cost-effective approach. At this time, there is only anecdotal evidence for benefit of various agents in patients with *RET* mutations, *HER2* mutations and amplification and other biomarkers. It is likely that this recommendation will evolve as prospective studies validating patient benefit in these subsets are reported. Furthermore, the increasing availability of “multiplex” testing may render this point moot. We emphasise that this is not a core recommendation since approved treatments are not available. Individual laboratories will have to judge whether this approach is the best use of resources, including tissue, especially in the context of supporting clinical trials.

**Recommendation 6: Is there a role for testing markers predictive of response to cytotoxic chemotherapy (ERCC1, RRM1, TS, etc.)?**

- Routine testing for these biomarkers is not recommended. No biomarker has been validated to predict benefit or resistance to currently available cytotoxic agents [II, D].
Numerous factors have been identified as potential predictive markers for specific chemotherapies in NSCLC, including ERCC1, BRCA1, RRM1 and thymidylate synthase (TS). Low ERCC1 expression by IHC [73] and mRNA [74-77] have been associated with sensitivity to cisplatin-based chemotherapy, but IHC results have not been reproducible [78, 79], and ERCC1 mRNA assessment requires further optimisation in prospective trials before this marker can be considered for routine use. Low BRCA1 mRNA expression also appears to confer sensitivity to the platinum agents, amongst other drugs, but confers resistance to the tubulin-targeting taxanes and vinca alkaloids [76, 77, 80-83]. BRCA1 may also be assessed by IHC [82-84], and both it and mRNA testing [76, 77, 80] appear reproducible, each lending themselves to evaluation in prospective randomised controlled trails in NSCLC. Data from translational studies suggest that IHC and mRNA expression of RRM1 are both prognostic and associated with benefit from gemcitabine therapy, but a prospective tailored treatment study has failed to bear this out [79, 80]. Low TS has been associated with improved clinical outcomes in patients with nonsquamous NSCLC treated with pemetrexed. In a prospective phase II study, high nuclear TS expression was correlated with poorer outcome, with a shorter overall survival, after treatment with second-line, single-agent pemetrexed [85]. Whilst encouraging, further prospective phase III studies are required to validate the reproducibility of the IHC and scoring systems used.

A number of other markers are currently under evaluation for predicting benefit or resistance to chemotherapy. There is sufficient evidence to encourage research and suggest success, but at present no biomarker has been adequately evaluated for use in the clinic to select patients for any chemotherapeutic agent.
Recommendation 7: What is the role of emerging technologies in contemporary biomarker testing?

- Multiplex platforms, including so-called ‘next generation’ technologies, for specific mutation panels are emerging as a cost and resource effective approach to simultaneous analysis of multiple potential targets. These are appropriate methods to test for mutations, provided that adequate external quality controls are in place [III, A].

- Global genomic analysis using next generation sequencing technology is a valuable research tool but has not yet been validated for clinical use [IV, C].

Next generation sequencing (NGS) is a powerful technology that allows sequencing of large numbers of DNA templates in a single test with high sensitivity and at relatively low cost [86]. Vast amounts of data have been generated using NGS for genome-wide analyses (GWA) of limited series of NSCLC samples, identifying potentially targetable genetic alterations that may be used to develop companion diagnostic tests for new drugs [87-91].

Multiplex testing platforms (SNaPshot, MassARRAY MALDI-TOF mass spectrometry, etc.) for detection of specific alterations [92] or targeted resequencing by NGS allows parallel testing for panels of validated genetic alterations which are therapeutic biomarkers.

Published data on NSCLC patients in the usual clinical setting of small biopsy/cytology samples remain relatively few.

Another potentially important application of NGS is ultra-deep sequencing (UDS), an extremely high sensitive approach for detecting mutations correlating with those in the
primary tumour, in body fluids, circulating tumour cells (CTCs), plasma or sera [93-95].

Sampling at different time points using this method may help to identify mutations evolving after different lines of treatment.

NGS holds great promise for the future, and although the technology is not yet being routinely used to guide treatment in NSCLC, this will soon change. Problems associated with the uptake of NGS include the lack of central regulation and standardisation for the platforms used, interpretation and validation of findings, reimbursement, DNA requirements and the implications of identifying rare mutations.

**Recommendation 8: Should laboratories participate in quality assurance programs?**

- Yes. Laboratories should have accreditation to conduct the test and should participate in external quality assurance to maintain accreditation [V, A].

Biomarker tests that are required for clinical decision making should be carried out in laboratories that are compliant with country-specific standards for clinical diagnostic testing. These standards normally require participation and success in an external quality assurance (EQA) programme [96, 97]. A number of different agencies oversee EQA programmes for molecular pathology in Europe (UKNEQAS, ESP, EMQN). Laboratories should also conduct frequent internal quality assurance assessments.
Recommendation 9: How should data from pathological, molecular and other biomarker testing be reported?

- Reports of pathological, molecular and other biomarker testing should include both results and interpretation that are readily understandable by oncologists and by non-specialist pathologists [V, A].
- Where appropriate, the analytic methodology, nature and quality of the sample should be described.
- Integration of pathology, molecular and other biomarker data for a case, usually in the form of a single report, is recommended [V, A].

Reports should be as clear, concise and unambiguous as possible. Recommendations for reporting NSCLC subtypes in small diagnostic samples were mentioned in Recommendation 2 and Table 2. Molecular data should always be reported in conjunction with the pathology of the tested sample and interpreted in that context [1-6], since the relevance of the molecular findings is dependent upon the tumour type and the quality of the test sample. Test methodology determines test sensitivity and specificity and this information should be available, with appropriate explanation, to allow the reader to assess test outcome significance. Sufficient detail should be present in the report to adequately describe test findings, allow their interpretation, and thereby guide therapy. The relevance of the findings to potential therapy choices should be indicated.

Conclusion

Molecular pathology and biomarker testing is an important development in the diagnosis and therapeutic stratification of lung cancer. The complexity of molecular abnormalities and
their assessment, combined with the challenge of delivering as much robust data as possible on very small diagnostic samples poses many questions for all involved in this process.

There is no single correct answer as to who should order the test; practice will depend on local organisation and health care systems, and decisions about how this is done require discussion between those involved. Reflex testing, ordered by the pathologist on making an appropriate diagnosis expedites testing, leading to faster turnaround time but may result in unnecessary tests being performed. Bespoke testing, at the behest of the oncologist, should ensure that only tests which are required are performed, but such testing will occur later, after the initial diagnosis is made.

Until a clinical role has been established for biomarkers in squamous cell carcinoma, routine biomarker testing in lung cancer cases in Europe is largely confined to adenocarcinomas, or in cases where this diagnosis cannot be excluded (non-squamous tumours). The mutual exclusivity, for all practical purposes, of clinically-relevant mutations in adenocarcinoma underpins the sequential testing approach where the commonest mutation (in Europe, KRAS mutation) would be sought, and if absent, the next commonest (EGFR mutation), and so on. Whilst economical in a service using individual mutation tests, this approach is very time-consuming, potentially wasteful of materials and not recommended. Parallel testing of multiple mutations on the same tumour (DNA) sample is becoming the standard, especially where multiplex mutation testing platforms are used. ALK testing may be practiced in parallel, perhaps using an IHC pre-screen, or may follow a negative mutation screen, although the benefits, in terms of time and tissue preservation, of parallel testing have already been discussed. In Recommendation 5 we considered the potential use of sequential testing for rare ROS1 and RET fusions in cases lacking other, more frequent,
mutations. In addition, accumulating evidence of change in molecular status post-treatment, and the emergence of molecular resistance may indicate a requirement for repeat biopsy at the time of tumour progression, if any change in biomarker status indicates a new targeted therapy validated by appropriate data. This is an evolving field.

These recommendations provide a framework for sound molecular pathology testing practice based upon current published evidence and expert opinion. This is a rapidly changing field, due to developments in molecular testing technology and in terms of emerging new targeted therapies which have predictive biomarkers. It is likely that these recommendations will require further updates to reflect changing practice.
**Table 1.** Levels of Evidence and Grades of Recommendation adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System†

<table>
<thead>
<tr>
<th>I</th>
<th>Evidence from at least one large randomised control trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomised trials without heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td>Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials demonstrated heterogeneity</td>
</tr>
<tr>
<td>III</td>
<td>Prospective cohort studies</td>
</tr>
<tr>
<td>IV</td>
<td>Retrospective cohort studies or case-control studies</td>
</tr>
<tr>
<td>V</td>
<td>Studies without control group, case reports, experts opinions</td>
</tr>
<tr>
<td>A</td>
<td>Strong evidence for efficacy with a substantial clinical benefit, strongly recommended</td>
</tr>
<tr>
<td>B</td>
<td>Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended</td>
</tr>
<tr>
<td>C</td>
<td>Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs,..), optional</td>
</tr>
<tr>
<td>D</td>
<td>Moderate evidence against efficacy or for adverse outcome, generally not recommended</td>
</tr>
<tr>
<td>E</td>
<td>Strong evidence against efficacy or for adverse outcome, never recommended</td>
</tr>
</tbody>
</table>

Table 2. Recommended nomenclature for small sample diagnosis of lung cancer

<table>
<thead>
<tr>
<th>Recommended nomenclature for small sample diagnosis of lung cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small cell carcinoma</td>
</tr>
<tr>
<td>Squamous Cell carcinoma</td>
</tr>
<tr>
<td>NSCLC, probably squamous cell carcinoma</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>NSCLC, probably adenocarcinoma</td>
</tr>
<tr>
<td>NSCLC-NOS(^1)</td>
</tr>
<tr>
<td>Carcinoid tumour(^2)</td>
</tr>
<tr>
<td>Others(^3)</td>
</tr>
</tbody>
</table>

1. This diagnosis is still acceptable if the immunohistochemistry cannot be performed, or is not predictive, the latter sometimes referred to as ‘null IHC’.
2. The distinction between typical and atypical carcinoid cannot be made reliably on small samples.
3. Rarely, for example, there may be sufficient tissue and morphological features to reliably diagnose rare tumours such as adenoid cystic or mucoepidermoid carcinoma.

**funding**

All costs relating to the consensus conference were covered from the European Society for Medical Oncology central funds. There was no external funding of the event or manuscript production.

**conflict of interest**

Prof. Stahel has reported Consultancy/honoraria: Abbott, Amgen, Astellas, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Genentech, Eli Lilly, Roche. Dr. Felip has reported Consultancy/honoraria: Lilly, GlaxoSmithKline, Pfizer, Roche, Boehringer Ingelheim. Dr. Peters has reported Consultancy/honoraria: Roche, Eli Lilly, AstraZeneca, Pfizer,
Boehringer Ingelheim, Bristol-Myers Squibb, Merck Serono, Daiichi Sankyo, Tesaro. Prof.
Kerr has reported Advisory Board and/or Speakers' bureau: Abbott Diagnostics, Roche,
AstraZeneca, Eli Lilly, Pfizer, Boehringer Ingelheim, Novartis, Merck Serono. Dr. Besse has
reported Research grants: Pfizer, Roche, Boehringer Ingelheim, AstraZeneca. Prof.
Vansteenkiste has reported that he is the Eli-Lilly Chair in Respiratory Oncology at the
Leuven University (research funding) and is the AstraZeneca Chair in Personalised Lung
Cancer Care at the Leuven University (research funding). Dr. Eberhardt has reported
Advisory board: GSK, Amgen, Novartis, Merck, Teva, Roche, AstraZeneca, Lilly, Boehringer,
Pfizer, BMS; Speakers' bureau: Roche, AZ, Lilly, Boehringer, Pfizer, GSK, Amgen, Novartis,
Hexal, Merck; Research grants: Eli Lilly. Dr. Edelman has reported Advisory board and/or
research funding: Genentech, Boehringer Ingelheim, Lilly, Endocyte. Prof. Baas has reported
Research grants: Pfizer. Dr. Reck has reported Advisory board: Hoffmann-La Roche, Lilly,
Pfizer, AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo; Speakers' honoraria: Hoffmann-La
Roche, Lilly, Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi-Sankyo. Dr. Paz-Ares has
reported Scientific advisor / Speakers' bureau: Lilly, Roche, Pfizer, Merck, Boehringer
Ingelheim, Desi pharma, Celgene. Dr. Meldgaard has reported Speakers' bureau: Roche. Dr.
Nicolson has reported Speakers' bureau: Roche, Lilly, Boehringer Ingelheim, Pfizer, Otsuka;
Research grants: Roche, Lilly, Boehringer Ingelheim, Pfizer, Novartis. Prof. Senan has
reported Research grants and honoraria: Varian Medical Systems; member of phase III trial
management group conducted by Lilly Oncology. Dr. Fairve-Finn has reported Research
grants AstraZeneca, Eli Lilly. Dr. Rocco has reported Speakers' bureau/grants: Covidien. Mr.
Lim has reported Research support: ScreenCell and PointHope; previously Speakers' bureau
for Roche and Imedex and Advisory board for Stratagen, Abbott Molecular and GSK; patent
pending with Clearbridge BioMedics; stock in Pfizer. Dr. Westeel has reported
Consultancy/honoraria: Lilly, Roche, Boehringer Ingelheim and AstraZeneca (for lectures);
Advisory role: Lilly, Roche and AstraZeneca; currently conducting research sponsored by
Merck Serono. Prof. Mok has reported: Speaker's bureau and Honoraria from: AstraZeneca,
Roche, Eli Lilly, Merck Serono, Eisai, BMS, BeiGene, AVEO, Pfizer, Taiho, Boehringer
Ingelheim, GSK Biologicals, Clovis Oncology; Research funding from AstraZeneca. Prof.
Bubendorf has reported Speakers' honoraria: Pfizer, Roche, and Abbott Molecular Inc.;
research supported by and stock held in Roche. Dr. Novello, Dr. Marchetti, Prof. Syrigos,
Prof. Smit, Dr. Adjei, Prof. Van Schil, Prof. Douillard, Prof. Weder, Prof. De Ruyscher, Dr. Le
Pechoux, Prof. De Leyn, Dr. Veronesi and Dr. Dooms have declared no potential conflicts of interest. Dr. Crinò and Prof. O'Byrne have not reported any potential conflicts of interest.

**appendix**

Members of the Panel

Rolf Stahel, Clinic of Oncology, University Hospital Zürich, Zürich, Switzerland; Enriqueta Felip, Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Solange Peters, Département d’Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Keith Kerr, Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Aberdeen, Scotland; Benjamin Besse, Thoracic Group, INSERM U981, Institut Gustave Roussy, Villejuif, France; Johan Vansteenkiste, Respiratory Oncology (Pulmonology), University Hospital KU Leuven, Leuven, Belgium; Wilfried Eberhardt, Department of Medical Oncology, West German Cancer Centre, University Hospital, University Duisburg-Essen, Essen, Germany; Martin Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States; Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin New Territories, Hong Kong, China; Ken O'Byrne, Department of Medical Oncology, St. James’s Hospital, Dublin, Ireland; Silvia Novello, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Orbassano, Italy; Lukas Bubendorf, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Antonio Marchetti, Center of Predictive Molecular Medicine and Center of Excellence on Ageing, University-Foundation, Chieti, Italy; Paul Baas, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Martin Reck, Department of Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf, Germany; Konstantinos Syrigos, Oncology Unit, Third Department of Medicine, Athens Chest Hospital Sotiria, Athens, Greece; Luis Paz-Ares, Hospital Universitario Virgen del Rocio, Sevilla, Spain; Egbert F. Smit, Department of Pulmonary Diseases, Vrije University Medical Centre (VUMC), Amsterdam, Netherlands; Peter Meldgaard, Aarhus University Hospital, Aarhus, Denmark; Alex Adjei, Medicine Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States; Marianne
Nicolson, Aberdeen Royal Infirmary Anchor Unit, Aberdeen, United Kingdom; Lucio Crinò, Department of Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy; Paul Van Schil, Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem (Antwerp), Belgium; Suresh Senan, Radiation Oncology, VU University Medical Centre, Amsterdam, The Netherlands; Corinne Faivre-Finn, Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Gaetano Rocco, Department of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation, IRCCS, Naples, Italy; Giulia Veronesi, Thoracic Surgery, European Institute of Oncology, Milan, Italy; Jean-Yves Douillard, Medical Oncology, Integrated Centers of Oncology R. Gauducheau, St. Herblain, France; Eric Lim, Imperial College and the Academic Division of Thoracic Surgery, Royal Brompton Hospital, London, United Kingdom; Christophe Dooms, Respiratory Oncology (Pulmonology), University Hospital KU Leuven, Leuven, Belgium; Walter Weder, Division of Thoracic Surgery, Universitätsspital Zürich, Zurich, Switzerland; Dirk De Ruysscher, Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; Cecile Le Pechoux, Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Paul De Leyn, Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium; Virginie Westeel, Service de Pneumologie Hôpital Jean Minjoz, Université de Franche-Comté, Besançon, France.
References


35. Bishop JA, Teruya-Feldstein J, Westra WH et al. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012 25, 405-415


45. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010; 11, 121-128


55. Wong DW, Leung EL, So KK et al.; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723–1733.


77. Wang L, Wei J, Qian X et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008 11;8:97.


84. Carser JE, Quinn JE, Michie CO et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol. 2011;123:492-8.


